From: DNA methylation gene-based models indicating independent poor outcome in prostate cancer
Characteristics | No. (%) of patients | |
---|---|---|
All patients | 367 | |
DPCaa | Yes | 99 (27) |
No | 268 (73) | |
Gleason score | Gleason 4 | 3 (0.8) |
Gleason 5 | 17 (4.6) | |
Gleason 6 | 171 (46.6) | |
Gleason 7 | 84 (22.9) | |
Gleason 8 | 43 (11.7) | |
Gleason 9 | 43 (11.7) | |
Gleason 10 | 6 (1.6) | |
PSA score | ≤4 | 138 (37.6) |
4 - ≤10 | 76 (20.7) | |
10 - ≤25 | 73 (19.9) | |
25 - ≤50 | 54 (14.7) | |
50 - 100 | 26 (7.1) | |
Extent of Disease | ≤0.06 | 108 (29.4) |
0.06 - ≤0.20 | 95 (25.9) | |
0.20 - ≤0.40 | 55 (15.0) | |
0.40 - ≤0.75 | 44 (12.0) | |
> 0.75 | 65 (17.7) | |
Age at diagnosis | ≤54 | 3 (0.8) |
>54 - 64 | 49 (13.4) | |
>64 - 74 | 253 (68.9) | |
>74 - 76 | 62 (16.9) |